Ionizable Lipid Nanoparticles for Repeat DNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for gene delivery suffer from non-optimal delivery efficiency and liver toxicity, particularly at higher doses, and viral vectors like adeno-associated vectors elicit humoral and cell-mediated immunity, compromising efficacy and re-administration.
Innovation Solution
Development of ionizable lipids with specific compositions and lipid nanoparticles (LNPs) that include cholesterol, PEG-lipid conjugates, and non-cationic lipids, optimized for enhanced efficacy, reduced toxicity, and improved pharmacokinetics, capable of encapsulating nucleic acids like closed-ended DNA (ceDNA).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cationic lipids are used for gene delivery, then nucleic acid delivery is achieved, but delivery efficiency is non-optimal and liver toxicity occurs at higher doses
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the amine group structure (e.g., N,N-dialkylamine groups with specific alkyl chain lengths), lipid tail composition, and headgroup configuration. These parameter changes optimize delivery efficiency while reducing liver toxicity by tuning the lipid's interaction with cellular membranes and metabolic pathways.
Solution Approach 2:
The invention employs composite lipid formulations combining ionizable lipids with specific structural features (e.g., N,N-dialkylamine groups, particular fatty acid chains) to create LNPs that achieve both high delivery efficiency and reduced hepatotoxicity. The composite structure allows synergistic effects where different lipid components contribute to encapsulation, stability, and safe cellular uptake.
2Reliability
If viral vectors like adeno-associated vectors are used, then gene delivery is achieved, but humoral and cell-mediated immunity is elicited compromising efficacy and re-administration
Solution Approach 1:
The patent extracts the essential gene delivery function from viral vectors while removing the immunogenic viral components. By using synthetic ionizable lipid nanoparticles instead of viral capsids, the invention retains nucleic acid encapsulation and cellular uptake capabilities while eliminating the proteins that trigger humoral and cell-mediated immune responses, enabling safe re-administration.
Solution Approach 2:
The invention replaces persistent viral vectors with disposable synthetic lipid nanoparticles that perform their delivery function and are then metabolized without triggering long-term immune memory. These synthetic carriers do not elicit lasting immune responses, allowing multiple treatment cycles unlike viral vectors that induce immunological memory.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNPs achieve efficient cellular uptake and nucleic acid release, providing improved therapeutic efficacy with reduced toxicity and allowing multiple doses without immune response, suitable for treating genetic disorders and rare diseases.
Implementation Method 1
the cationic amine moiety and a polyanion nucleic acid interact electrostatically to form a positively charged liposome or lipid membrane structure
Data Source
AI summary
Provided herein are lipids having the Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).